# Magnesium Carbonate **Canonical URL:** https://ingredients.hermeticasuperfoods.com/ingredients/magnesium-carbonate **Data Source:** Hermetica Superfoods Ingredient Encyclopedia **Updated:** 2026-04-04 **Evidence Score:** 2 / 10 **Category:** Mineral **Also Known As:** MgCO₃, Magnesite, Carbonic acid magnesium salt, Light magnesium carbonate, Basic magnesium carbonate, Magnesium carbonate trihydrate, E504, Chalk substitute, Gymnastic chalk ## Overview Magnesium carbonate is an inorganic magnesium salt (MgCO3) that acts as a phosphate binder in the gastrointestinal tract by forming insoluble magnesium phosphate complexes, preventing phosphate absorption. It is primarily used in clinical settings for managing hyperphosphatemia in chronic kidney disease and hemodialysis patients. ## Health Benefits • Effectively controls serum phosphate levels in hemodialysis patients without causing hypercalcemia (Strong evidence: multiple RCTs, PMID: 8770963, 18193489) • Reduces calcium intake burden by 48% compared to calcium acetate while maintaining phosphate control (Moderate evidence: RCT n=32, PMID: 17971314) • Allows higher vitamin D (calcitriol) dosing without hypercalcemia risk (Strong evidence: crossover trial, PMID: 8770963) • May prevent progression of coronary artery calcification in dialysis patients (Preliminary evidence: pilot study n=11, PMID: 19469885) • Provides non-inferior phosphate control to sevelamer-HCl at 80% lower cost (Moderate evidence: large trial referenced in PMID: 26069822) ## Mechanism of Action Magnesium carbonate dissociates in the acidic environment of the stomach, releasing Mg2+ ions that bind dietary phosphate to form insoluble magnesium phosphate (Mg3(PO4)2), which is excreted in feces rather than absorbed. This reduces intestinal phosphate transport mediated by sodium-phosphate cotransporters (NaPi-IIb) in the small intestine. Unlike calcium-based binders, magnesium carbonate does not contribute to calcium loading, avoiding activation of the calcium-sensing receptor (CaSR) pathways that can suppress PTH and cause hypercalcemia. ## Clinical Summary Multiple randomized controlled trials, including studies indexed under PMID 8770963 and PMID 18193489, demonstrate that magnesium carbonate effectively reduces serum phosphate in hemodialysis patients to levels comparable to calcium acetate. One RCT (n=32) found magnesium carbonate reduced elemental calcium intake burden by approximately 48% versus calcium acetate while maintaining equivalent phosphate control. Evidence is strongest for the hyperphosphatemia indication, with moderate-to-strong support from multiple RCTs; however, evidence for general magnesium supplementation efficacy relative to other forms such as magnesium glycinate or citrate is limited. Long-term [cardiovascular](/ingredients/condition/heart-health) and mortality outcome data specific to magnesium carbonate as a phosphate binder remain an area of ongoing investigation. ## Nutritional Profile Magnesium Carbonate (MgCO3) is an inorganic mineral salt, not a macronutrient source. It contains no protein, fat, carbohydrates, or fiber. Primary active component is elemental magnesium at approximately 28-29% by molecular weight (MgCO3 molecular weight: 84.31 g/mol; Mg atomic weight: 24.31 g/mol). A typical supplemental dose of 400-500mg MgCO3 yields approximately 115-145mg elemental magnesium. As a carbonate salt, it also releases carbon dioxide (CO2) and carbonate/bicarbonate ions upon contact with gastric acid, which may contribute mild antacid activity. Contains no vitamins, amino acids, or organic bioactive compounds. Bioavailability: Magnesium from carbonate salts is considered moderately bioavailable; absorption estimated at 30-40% under normal gastric acid conditions, occurring primarily in the small intestine via both active (TRPM6/TRPM7 channels) and passive paracellular transport. Bioavailability is reduced in achlorhydria or with proton pump inhibitor use due to dependence on acidic environment for ionization. Compared to magnesium oxide (~4% bioavailability) it performs better, but is less bioavailable than magnesium citrate (~90%) or magnesium glycinate. Basic magnesium carbonate (hydrated form: 4MgCO3·Mg(OH)2·4H2O) contains approximately 40% elemental magnesium by weight and is the more commonly used commercial form. No caloric value; negligible osmotic load at standard doses. ## Dosage & Preparation Clinically studied doses range from 86 mg elemental magnesium per dose, titrated individually up to several grams daily for phosphate control. Typically combined with calcium carbonate in ratios of 86:100 mg (Mg:Ca). Used with low dialysate magnesium (0.6 mg/dL) to prevent hypermagnesemia. Consult a healthcare provider before starting any new supplement. ## Safety & Drug Interactions The most common side effects are gastrointestinal, including diarrhea, loose stools, and nausea, owing to the osmotic and neutralizing properties of the carbonate anion. Hypermagnesemia is a serious risk in patients with impaired renal function, as magnesium is renally cleared; serum magnesium must be monitored in dialysis populations using this agent. Magnesium ions can chelate and reduce the absorption of tetracycline antibiotics, fluoroquinolones, bisphosphonates, and levothyroxine, requiring dosing separation of at least two hours. Magnesium carbonate is generally avoided in patients with severe renal insufficiency not on dialysis, and safety data in pregnancy are insufficient to establish a formal recommendation beyond standard magnesium dietary requirements. ## Scientific Research Clinical evidence comes primarily from trials in hemodialysis and chronic kidney disease patients, including a 6-month RCT (n=40, PMID: 18193489) and crossover study (n=14, PMID: 8770963) demonstrating effective phosphate control. A pilot trial (n=32, PMID: 17971314) showed 70.6% of patients met phosphate targets with significantly reduced calcium intake. ## Historical & Cultural Context No evidence of traditional medicinal use exists in herbal, Ayurvedic, or other historical systems. Biomedical applications are entirely modern, beginning in the 1990s specifically for renal phosphate control in dialysis patients. ## Synergistic Combinations Calcium carbonate, vitamin D (calcitriol), low-magnesium dialysate, phosphate-restricted diet ## Frequently Asked Questions ### How does magnesium carbonate compare to calcium acetate for phosphate binding in dialysis? Clinical trials show magnesium carbonate achieves equivalent serum phosphate control to calcium acetate in hemodialysis patients while reducing elemental calcium intake by roughly 48%, lowering the risk of hypercalcemia. This makes it a preferred option for patients already at risk of calcium overload or vascular calcification associated with calcium-based binders. ### What is the typical dosage of magnesium carbonate used as a phosphate binder? In clinical trials for hyperphosphatemia management, magnesium carbonate doses typically ranged from approximately 400 to 800 mg of elemental magnesium per day, divided with meals to maximize phosphate binding in the gut. Exact dosing must be individualized based on serum phosphate targets and monitored magnesium levels, particularly in dialysis patients. ### Can magnesium carbonate raise magnesium levels dangerously? Yes, hypermagnesemia is a clinically relevant risk, especially in individuals with reduced kidney function, because the kidneys are the primary route of magnesium excretion. Symptoms of elevated serum magnesium include nausea, hypotension, bradycardia, and in severe cases neuromuscular paralysis; routine serum magnesium monitoring is essential when using magnesium carbonate therapeutically in renal patients. ### Does magnesium carbonate absorb well as a general magnesium supplement? Magnesium carbonate has relatively low bioavailability as a general dietary supplement compared to organic forms such as magnesium glycinate or magnesium citrate, because the carbonate salt requires significant gastric acid for ionization and is partially converted to magnesium oxide in the gut. For individuals with low stomach acid or those seeking high bioavailability magnesium supplementation, organic salt forms are generally preferred by clinicians. ### What drugs interact with magnesium carbonate and how should they be managed? Magnesium carbonate can significantly impair the absorption of tetracycline and fluoroquinolone antibiotics, bisphosphonates such as alendronate, and levothyroxine by forming insoluble chelation complexes in the gastrointestinal tract. To minimize this interaction, these medications should be taken at least two hours before or four to six hours after magnesium carbonate administration. ### Is magnesium carbonate safe for patients with kidney disease or on dialysis? Magnesium carbonate is specifically designed for hemodialysis patients and has strong clinical evidence supporting its safety in this population, as it effectively binds phosphate while avoiding the hypercalcemia risk associated with calcium-based binders. However, patients with severe renal impairment not yet on dialysis should use it cautiously and only under medical supervision, as kidney disease can impair magnesium excretion. Serum magnesium and phosphate levels should be monitored regularly to ensure therapeutic efficacy and prevent hypermagnesemia. ### How does magnesium carbonate's phosphate-binding mechanism differ from other mineral forms of magnesium? Magnesium carbonate's alkaline carbonate structure allows it to bind phosphate ions in the gastrointestinal tract, making it function as a phosphate binder rather than primarily as a bioavailable magnesium source for general supplementation. Unlike magnesium oxide or magnesium citrate, which are absorbed systemically to raise serum magnesium, magnesium carbonate works locally in the gut to reduce dietary phosphate absorption before it enters the bloodstream. This unique mechanism makes it particularly valuable in dialysis management where phosphate control is critical, but less suitable as a standalone magnesium supplement for non-dialysis populations. ### What are the gastrointestinal side effects associated with magnesium carbonate and how do they compare to calcium-based phosphate binders? Magnesium carbonate commonly causes loose stools or diarrhea due to magnesium's osmotic effects in the intestine, though this is generally less severe than the constipation frequently reported with calcium acetate. The diarrheal effect can sometimes be beneficial for dialysis patients at risk of constipation, but dosing adjustments or combination therapy with calcium binders may be needed if GI symptoms become problematic. Tolerability varies among individuals, and gradual dose titration can help minimize gastrointestinal disturbance. --- *Source: Hermetica Superfoods Ingredient Encyclopedia — https://ingredients.hermeticasuperfoods.com* *License: CC BY-NC-SA 4.0 — Attribution required. Commercial use: admin@hermeticasuperfoods.com*